Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 500672 | NSE Symbol : NOVARTIND | ISIN : INE234A01025 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
27-Dec-2024	28-Jan-2025	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve The intimation is filed to inform that the Board Meeting of the Company shall be held on Tuesday January 28 2025 for approval of Quarterly Financial Results for the Quarter ended as on December 31 2024. We hereby inform that the Board of Directors ('Board') of the Company at its Meeting held today i.e. January 28, 2025 inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024 as recommended by the Audit Committee of the Company. (As Per BSE Announcement Dated on: 28/01/2025)
27-Sep-2024	25-Oct-2024	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the Unaudited Financial Results for the quarter ended September 30 2024 Filing of the outcome of Board Meeting and Unaudited Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024)
27-Jun-2024	29-Jul-2024	Quarterly Results	Intimation in relation to Board meeting and closure of Trading window for period July 01, 2024 to July 31, 2024 Outcome - Unaudited Financial Results for the Quarter ended June 30, 2024 (As Per BSE Announcement dated on 29.07.2024)
28-Jun-2024	28-Jun-2024	Change in Directors	Board Meeting outcome for meeting of Board of Directors of Novartis India Limited held on June 28, 2024 for appointment of additional Director (designated as Whole Time Director)
27-Mar-2024	10-May-2024	Accounts	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the year ended March 31 2024; and recommend dividend on equity shares of the Company if any for the financial year ended March 31 2024 Final Dividend & Audited Results (As per BSE Bulletin dated on 27/03/2024) Outcome of the Meeting of the Board of Directors of Novartis India Limited ('the Company') held on May 10, 2024 Corporate Action - Board approved dividend Corporate Action - fixes book closure (As Per BSE Announcement dated on 10.05.2024)
08-May-2024	08-May-2024	Change in Other Executives	The Resolution is passed approving the appointment of Company Secretary and Compliance officer of Novartis India Limited. The Resolution is passed approving the appointment of Company Secretary and Compliance officer of Novartis India Limited. Appointment of Company Secretary and Compliance officer in Novartis India Limited. Approval for the appointment of Company Secretary and Compliance officer by Novartis India Limited.
17-Feb-2024	17-Feb-2024	Change in Directors	Outcome of the meeting of the Board of Directors of Novartis India Limited held today i.e. Saturday, February 17, 2024 Cessation by virtue of completion of tenure of Mr. Jai Hiremath (DIN: 00062203) as an Independent Director Appointment of Ms. Gira Sardesai (DIN: 02610502) as an Additional Director (Designated as Non-Executive and Independent Director)
27-Dec-2023	25-Jan-2024	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31 2023 Outcome of the Meeting of the Board of Directors of Novartis India Limited held today i.e. Thursday, January 25, 2024 Financial Results for the third quarter and nine months ended December 31, 2023 (As per BSE Announcement Dated on 25/01/2024)
30-Sep-2023	27-Oct-2023	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve the Unaudited Financial Results for the quarter and half year ended September 30 2023 Financial Results / Outcome of the Meeting of the Board of Directors of Novartis India Limited held today i.e. Friday, October 27, 2023 Outcome of the Meeting of the Board of Directors of Novartis India Limited held today i.e. Friday, October 27, 2023 (As per BSE Announcement Dated on 27/10/2023)
30-Jun-2023	26-Jul-2023	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30 2023 Outcome of the Meeting of the Board of Directors of Novartis India Limited held today i.e. Wednesday, July 26, 2023 Results - Financial Results for June 30, 2023 (As Per BSE Announcement dated on 26.07.2023)
31-Mar-2023	10-May-2023	Accounts	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2023 inter alia to consider and approve the Audited Financial Results of the Company for the year ended March 31 2023; and recommend dividend on equity shares of the Company if any for the financial year ended March 31 2023 Intimation of Newspaper Advertisement by Novartis India Limited regarding the Notice of meeting of the Board of Directors of the Company (As Per BSE Announcement Dated on 01/04/2023) The Board has recommended the following dividend for the financial year ended March 31, 2023, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting (AGM): a) Final dividend of 10.00 (Rupees Ten Only) per equity share of the face value of 5 each b) One-time Special dividend of 37.50 (Rupees Thirty-Seven and Paise Fifty Only) per equity share of the face value of 5 each, on occasion of Companys 75th Anniversary The total dividend amounts to 47.50 (Rupees Forty-Seven and Paise Fifty Only) per equity share of the face value of 5 each. Accordingly, the dividend, if approved by the shareholders, will be paid on or after August 02, 2023. (As Per BSE Bulletin Dated on 10.05.2023) Outcome of the Meeting of the Board of Directors of Novartis India Limited held on May 10, 2023 Audited Financial Results for the quarter and year ended March 31, 2023 (As per BSE Announcement Dated on 10/05/2023)
27-Dec-2022	08-Feb-2023	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the third quarter ending on December 31 2022 Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2022 (As Per BSE Announcement dated on 08.02.2023)
30-Sep-2022	09-Nov-2022	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve the Unaudited Financial Results for the second quarter and half year ending on September 30 2022 Outcome of the Meeting of the Board of Directors of Novartis India Limited (''the Company'') held today i.e. Wednesday, November 09, 2022 Resignation of Ms. Monaz Noble (DIN: 03086192) as Director Appointment of Ms. Shilpa Joshi (DIN: 09775615) as Additional Director (designated as Whole-Time Director and Chief Financial Officer) of the Company (As Per BSE Announcement Dated on 09/11/2022)
30-Jun-2022	27-Jul-2022	Quarterly Results	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2022 inter alia to consider and approve the Unaudited Financial Results of the Company for the first quarter ending on June 30 2022. Outcome of the Meeting of the Board of Directors of Novartis India Limited held today i.e. Wednesday, July 27, 2022 (As Per BSE Announcement Dated on 27.07.2022)
31-Mar-2022	19-May-2022	Final Dividend	NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 inter alia to consider and approve the Audited financial results of the Company for the fourth quarter and financial year ending on March 31 2022 ('said results') and recommendation of final dividend on Equity Share if any for the said year. The Board has recommended final dividend of Rs. 10 per equity share (of the face value of Rs. 5 each) for the financial year ended March 31, 2022, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting ('AGM'). Accordingly, the said final dividend, if approved by the shareholders, will be paid on or after August 2, 2022. Outcome of the Meeting of the Board of Directors of Novartis India Limited ('the Company') held on May 19, 2022 The Board has recommended the appointment of M/s. B S R & Co. LLP, Chartered Accountants (ICAI FRN: 101248W/W-100022) as Statutory Auditors of the Company for a term of 5 (five) years to hold office from the conclusion of 74th AGM till the conclusion of 79th AGM of the Company subject to the approval of the shareholders at the ensuing AGM. Brief Profile of M/s. B S R & Co. LLP is enclosed herewith. (As Per BSE Announcement Dated on 19.05.2022)

1 2

LOGIN HERE

Novartis India Ltd

Board Meeting